The COVID-19 vaccine, developed by Oxford University and manufactured by pharmaceutical company AstraZeneca, is reported to be highly effective based on the late-stage trials.
Over 20,000 volunteers participated in the trials in Brazil and the United Kingdom (UK).
Based on the trial, the vaccine can provide an average efficacy of 70% protection against the virus.
Researchers also said its protection rate can scale up to 90% efficacy rate when given as a half dose, followed by a full dose at least one month apart.
They also considered the results a success, even though the vaccines developed by Pfizer and Moderna are reported to be 95 per cent and 94.5 percent effective respectively.
However, researchers said the vaccine developed by Oxford is more affordable and easier to ship across countries.
The UK government already pre-ordered 100 million doses of the Oxford vaccine. AstraZeneca said they will manufacture three billion doses by next year. AAC (with reports from Jovic Bermas)
The post Oxford COVID-19 vaccine ‘highly effective’ based on trial appeared first on UNTV News.